A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

February 10, 2025

Study Completion Date

February 10, 2025

Conditions
Rheumatoid ArthritisArthritis, RheumatoidArthritis
Interventions
DRUG

Imvotamab

Administered intravenously

DRUG

Placebo

0.9% sodium chloride administered intravenously

Trial Locations (18)

28144

Accelacare - Salisbury, Salisbury

32855

Omega Research MetroWest, Orlando

33180

Arthritis and Rheumatic Disease Specialties, Aventura

33324

Integral Rheumatology & Immunology Specialists, Plantation

75150

Southwest Rheumatology Research, Mesquite

80045

University of Colorado Hopsital - Anschutz Medical Campus, Aurora

85306

Arizona Arthritis & Rheumatology Research, PLLC, Glendale

92108

Triwest Research Associates, San Diego

94578

East Bay Rheumatology Medical Group, San Leandro

860001

Arizona Arthritis & Rheumatology Research, PLLC, Flagstaff

Unknown

Centrum Reumatologii i Rehabilitacji NOVA REUMA, Bialystok

Nova Reuma Domyslawska i Rusilowicz Spólka Partnerska Lekarza Reumatologa i Fizjoterapeuty, Bialystok

Medicover Integrated Clinical Services (MCIS) Centrum Medyczne Bydgoszcz, Bydgoszcz

Niepubliczny Zakład Opieki Zdrowotnej Lecznica MAK-MED w Nadarzynie, Nadarzyn

Med Polonia Sp. z o. o. - Obornicka, Poznan

Medyczne Centrum Hetmanska, Poznan

Prywatna Praktyka Lekarska Prof. Dr Hab. Med. Paweł Hrycaj, Poznan

Reumedika s.c. Wiesława i Łukasz Porawscy, Poznan

Sponsors
All Listed Sponsors
lead

IGM Biosciences, Inc.

INDUSTRY